Efficacy of High Doses of Both Pegylated Interferon Alfa-2a and Ribavirin for Retreatment of HIV-coinfected Patients With Liver Cirrhosis Due to HCV Genotype 1 or 4 Nonresponders to Previous Standard Therapy
Phase of Trial: Phase II/III
Latest Information Update: 06 Oct 2015
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- 29 Dec 2011 Actual patient number is 25 according to ClinicalTrials.gov.
- 29 Dec 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Nov 2009 New trial record